An observational study in TNBC - Triple-Negative Breast Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.
Sponsored by Fudan University · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.
Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is one of 7 that started in 2025, is one of 3 observational ones, reaches primary completion later than 18 of the 38 other live ones, and was the 51st registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18–80
Fudan University · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 44 · Phase 3 16 · Phase 4 2
First in 2007; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 110 across the 62 interventional studies, 300 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
6 of the studies in Triple Negative Breast Neoplasms by Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
| NCT05076682Fudan UniversityReverse Triple Negative Immune Resistant Breast Cancer | 2026-12-31 |
| NCT06798506Fudan UniversityReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer | 2027-01-15 |
| NCT07705438Fudan UniversityGranzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | 2027-05-28 |
| NCT06731153Fudan UniversityJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this trial is to explore the real-world patient-reported health-related quality of life (HRQOL), functioning, symptoms and symptom tolerability of sacituzumab govitecan or chemotherapy of the physician's choice for Chinese mTNBC patients. Evaluation of HRQOL and functioning using the EORTC QLQ-C30 and QLQ-BR45 questionnaires, including change from baseline and time to deterioration in each scale or item. Treatment-related symptoms and tolerability were assessed using the Patient-Reported Outcomes of the PRO-CTCAE and PGI-TT questionnaires.
Patients have been diagnosed with metastatic triple-negative breast cancer (mTNBC). ER, PgR, and HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives Sacituzumab govitecanStudies of Sacituzumab govitecanSacituzumab govitecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Patient-reported HRQOL
Patient-reported health-related quality of life (HRQOL) evaluated by EORTC QLQ-C30 questionnaires
Time frame: 6 weeks
Patient-reported functioning
Patient-reported functioning evaluated by QLQ-BR45 questionnaires.
Time frame: 6 weeks
Patient-reported symptoms
Treatment-related symptoms were assessed using the Patient-Reported Outcomes of the PRO-CTCAE.
Time frame: 6 weeks
Patient-reported tolerability
Treatment-related tolerability were assessed using the Patient-Reported Outcomes of the PGI-TT questionnaires.
Time frame: 6 weeks
PFS
Progression free survival
Time frame: 6 weeks
ORR
Overall Response Rate
Time frame: 6 weeks
CBR
Clinical benefit Rates
Time frame: 6 weeks
OS
Overall Survival
Time frame: 6 weeks
Safety
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: 6 weeks
Start is estimated for Feb 2025; primary completion for Jan 2027, 23 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →